Membrane-type 1 matrix metalloproteinase mRNA expression in colorectal cancer

被引:2
|
作者
Sardinha, TC
Nogueras, JJ
Xiong, H
Weiss, EG
Wexner, SD
Abramson, S
机构
[1] Cleveland Clin Florida, Dept Colorectal Surg, Ft Lauderdale, FL 33309 USA
[2] Cleveland Clin Florida, Res Lab, Ft Lauderdale, FL 33309 USA
关键词
matrix metalloproteinase; colorectal adenocarcinoma; metastases;
D O I
暂无
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
PURPOSE: Membrane-type matrix metalloproteinases are recently described proteolytic enzymes belonging to the matrix metalloproteinase family. Initial studies have indicated that membrane-type matrix metalloproteinases are involved in tumor invasion and metastasis. Membrane-type 1 matrix metalloproteinase is the first membrane-type matrix metalloproteinase to be described. The aim of this study was to investigate the expression of membrane-type 1 matrix metalloproteinase mRNA in colorectal cancer. METHODS: Samples were collected from surgical specimens of patients with colorectal adenocarcinoma and were immediately frozen in liquid nitrogen and stored at -80 degrees C until processed. Both normal and cancer tissue was taken from each patient. TNM stage, tumor differentiation, mucin production, and vascular invasion were assessed. Northern blotting was used to quantify membrane-type 1 matrix metalloproteinase mRNA levels in the samples using a membrane-type 1 matrix metalloproteinase cDNA clone. X-ray film images were digitized and densitometry was used to quantify bands. All samples were normalized against 18S rRNA levels. Results are expressed as the ratio of cancer to normal tissue levels. Statistical analysis was performed using analysis of variance, with P < 0.05 accepted as the level of significance. RESULTS: A total of 32 samples were prospectively analyzed. The correlation between TNM stage and increased expression of membrane-type 1 matrix metalloproteinase mRNA in cancer tissue over normal tissue is expressed in the mean ratio of cancer to normal tissue expression for Stages I through IV, respectively: 1.4 +/- 0.2 (12 patients); 4.1 +/- 2.6 (8 patients); 3.4 +/- 3 (7 patients); and 4.5 +/- 5 (5 patients). Stage I is significantly different from Stages II and IV (P < 0.05). These preliminary results show an overall increasing trend in membrane-type 1 matrix metalloproteinase expression with increasing tumor stage. However, there was no correlation between membrane-type 1 matrix metalloproteinase expression and mucin production, degree of tumor differentiation, or vascular invasion. CONCLUSION: Preliminary results indicate that membrane-type 1 matrix metalloproteinase levels correlate with increasing tumor stage.
引用
收藏
页码:389 / 395
页数:7
相关论文
共 50 条
  • [41] Altered plasma matrix metalloproteinase-9/tissue metalloproteinase-1 concentration during the early postoperative period in patients with colorectal cancer
    Kirman, I
    Jain, S
    Cekic, V
    Belizon, A
    Balik, E
    Sylla, P
    Arnell, T
    Forde, K
    Whelan, RL
    SURGICAL ENDOSCOPY AND OTHER INTERVENTIONAL TECHNIQUES, 2006, 20 (03): : 482 - 486
  • [42] Involvement of Catechols in Acteoside in the Activation of Promatrix Metalloproteinase-2 and Membrane Type-1-Matrix Metalloproteinase Expression via a Phosphatidylinositol-3-Kinase Pathway in Human Dermal Fibroblasts
    Si, Nan
    Kanazawa, Hajime
    Okuyama, Katsuki
    Imada, Keisuke
    Wang, Hongjie
    Yang, Jian
    Zhao, Haiyu
    Bian, Baolin
    Ito, Akira
    Sato, Takashi
    BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2018, 41 (10) : 1530 - 1536
  • [43] Novel inhibitors of urokinase-type plasminogen activator and matrix metalloproteinase expression in metastatic cancer cell lines
    Cakarovski, K
    Leung, JY
    Restall, C
    Carin-Carlson, A
    Yang, E
    Perlmutter, P
    Anderson, R
    Medcalf, R
    Dear, AE
    INTERNATIONAL JOURNAL OF CANCER, 2004, 110 (04) : 610 - 616
  • [44] Membrane type 1-matrix metalloproteinase is involved in the migration of human monocyte-derived dendritic cells
    Yang, Mei-Xiang
    Qu, Xun
    Kong, Bei-Hua
    Lam, Queenie L. K.
    Shao, Qian-Qian
    Deng, Bi-Ping
    Ko, King-Hung
    Lu, Liwei
    IMMUNOLOGY AND CELL BIOLOGY, 2006, 84 (06) : 557 - 562
  • [45] The ratio of Matrix Metalloproteinase to E-cadherin expression: A pilot study to assess mRNA and protein expression among African American prostate cancer patients
    Pettaway, Curtis A.
    Song, Renduo
    Wang, Xuemei
    Sanchez-Ortiz, Ricardo
    Spiess, Philippe E.
    Strom, Sara
    Troncoso, Patricia
    PROSTATE, 2008, 68 (13) : 1467 - 1476
  • [46] Matrix metalloproteinase MMP1 and MMP9 genes expression in breast cancer tissue
    Mohammadian, Hassan
    Sharifi, Rasoul
    Amirdehi, Somayyeh Rezanezhad
    Taheri, Elham
    Bedoustani, Ahmad Babazadeh
    GENE REPORTS, 2020, 21
  • [47] Matrix metalloproteinase expression and molecular interaction network analysis in gastric cancer
    Xu, Jianting
    E, Changyong
    Yao, Yongfang
    Ren, Shuangchun
    Wang, Guoqing
    Jin, Haofan
    ONCOLOGY LETTERS, 2016, 12 (04) : 2403 - 2408
  • [48] Tissue levels of active matrix metalloproteinase-2 and-9 in colorectal cancer
    Waas, ET
    Lomme, RMLM
    DeGroot, J
    Wobbes, T
    Hendriks, T
    BRITISH JOURNAL OF CANCER, 2002, 86 (12) : 1876 - 1883
  • [49] Developmental regulation of membrane type-5 matrix metalloproteinase (MT5-MMP) expression in the rat nervous system
    Jaworski, DM
    BRAIN RESEARCH, 2000, 860 (1-2) : 174 - 177
  • [50] Impact of plasma tissue inhibitor of matrix metalloproteinase-1 on long-term survival in patients with colorectal cancer
    Yukawa, Norio
    Yoshikawa, Takaki
    Akaike, Makoto
    Sugimasa, Yukio
    Rino, Yasushi
    Masuda, Munetaka
    Imada, Toshio
    ONCOLOGY, 2007, 72 (3-4) : 205 - 208